LEGN

Legend Biotech is a clinical-stage and commercial-stage biopharmaceutical company focused on oncology through chimeric antigen receptor T-cell (CAR-T) therapy, with CARVYKTI approved by the FDA in February 2022 for certain hematologic malignancies and commercialized through a profit-sharing collaboration with Janssen. The company has also entered into a licensing agreement with Novartis involving additional programs in oncology, and maintains a pipeline of CAR-T and other cell therapy candidates in development supported by partnerships and upfront payments totaling over $1 billion in milestone commitments.

Pipeline

Catalyst Calendar